SCHEMBL1764729

SCHEMBL1764729

[2H]C([2H])([2H])C(c1cc(Br)cc(Br)c1O)(C([2H])([2H])[2H])C([2H])([2H])[2H]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.50
TSHR P16473 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
GABRA1 P14867 2/20 0.45
GABRB1 P18505 2/20 0.45
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45
IGF1R P08069 1/20 0.39
CISD1 Q9NZ45 1/20 0.39
AKR1C4 P17516 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
ERN1 O75460 1/20 0.38
ALOX15 P16050 4/20 0.38
ALOX12 P18054 4/20 0.38
HIF1A Q16665 3/20 0.38
HPGD P15428 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1530860 0.85 TSHR (0.56) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL30218650 0.85 TSHR (0.56) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL22408773 0.81 TSHR (0.48) CYP3A4TSHRTDP1GABRA1GABRB2
SCHEMBL7191865 0.77 CYP3A4 (0.56) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL5597001 0.73 TSHR (0.52) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL49614 0.73 CA2 (0.64) CYP3A4TSHRTDP1ALOX15HIF1A
SCHEMBL282136 0.72 CYP3A4 (0.56) CYP3A4TSHRTDP1GABRA1GABRB1
SCHEMBL1764594 0.72 ALDH1A1 (0.45) TSHRTDP1ERN1ALOX15HPGD
Methylamine SCHEMBL3205669 0.70 CA2 (0.58) CYP3A4TSHRTDP1ALOX15HIF1A
SCHEMBL28572779 0.70 CA2 (0.58) CYP3A4TSHRTDP1ALOX15HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383824-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2013-02-26 US disclosed
EP-2501679-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-09-26 EP disclosed
WO-2011061243-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-05-26 WO disclosed
US-20110123489-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC (US) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110123489-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HCCS, EIF2AK2, RNASE1 CYP3A4 60/4885TSHR 3238/4885TDP1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.